JP5385274B2 - ホスファプラチン、ならびにシスプラチンおよびカルボプラチンに対し耐性を有する癌の治療におけるその使用 - Google Patents

ホスファプラチン、ならびにシスプラチンおよびカルボプラチンに対し耐性を有する癌の治療におけるその使用 Download PDF

Info

Publication number
JP5385274B2
JP5385274B2 JP2010520294A JP2010520294A JP5385274B2 JP 5385274 B2 JP5385274 B2 JP 5385274B2 JP 2010520294 A JP2010520294 A JP 2010520294A JP 2010520294 A JP2010520294 A JP 2010520294A JP 5385274 B2 JP5385274 B2 JP 5385274B2
Authority
JP
Japan
Prior art keywords
platinum
isolated
cancer
composition
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010520294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535803A (ja
Inventor
ボース，ラシンドラ，エヌ．
Original Assignee
オハイオ ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オハイオ ユニバーシティー filed Critical オハイオ ユニバーシティー
Publication of JP2010535803A publication Critical patent/JP2010535803A/ja
Application granted granted Critical
Publication of JP5385274B2 publication Critical patent/JP5385274B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010520294A 2007-08-06 2008-08-06 ホスファプラチン、ならびにシスプラチンおよびカルボプラチンに対し耐性を有する癌の治療におけるその使用 Active JP5385274B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95412607P 2007-08-06 2007-08-06
US60/954,126 2007-08-06
US97392607P 2007-09-20 2007-09-20
US60/973,926 2007-09-20
PCT/US2008/072398 WO2009021082A2 (en) 2007-08-06 2008-08-06 Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013120309A Division JP5647300B2 (ja) 2007-08-06 2013-06-07 ホスファプラチン、ならびにシスプラチンおよびカルボプラチンに対し耐性を有する癌の治療におけるその使用

Publications (2)

Publication Number Publication Date
JP2010535803A JP2010535803A (ja) 2010-11-25
JP5385274B2 true JP5385274B2 (ja) 2014-01-08

Family

ID=40342030

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010520294A Active JP5385274B2 (ja) 2007-08-06 2008-08-06 ホスファプラチン、ならびにシスプラチンおよびカルボプラチンに対し耐性を有する癌の治療におけるその使用
JP2013120309A Active JP5647300B2 (ja) 2007-08-06 2013-06-07 ホスファプラチン、ならびにシスプラチンおよびカルボプラチンに対し耐性を有する癌の治療におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013120309A Active JP5647300B2 (ja) 2007-08-06 2013-06-07 ホスファプラチン、ならびにシスプラチンおよびカルボプラチンに対し耐性を有する癌の治療におけるその使用

Country Status (12)

Country Link
US (4) US7700649B2 (https=)
EP (2) EP2668949A1 (https=)
JP (2) JP5385274B2 (https=)
CN (1) CN101801369B (https=)
CY (1) CY1115504T1 (https=)
DK (1) DK2173337T3 (https=)
ES (1) ES2495743T3 (https=)
HR (1) HRP20140808T1 (https=)
PL (1) PL2173337T3 (https=)
PT (1) PT2173337E (https=)
SI (1) SI2173337T1 (https=)
WO (2) WO2009021081A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2495743T3 (es) * 2007-08-06 2014-09-17 Ohio University Fosfaplatinos y su uso en el tratamiento de cánceres resistentes a cisplatino y carboplatino
CN108210516A (zh) * 2010-06-04 2018-06-29 俄亥俄大学 磷铂及其在治疗癌症中的用途
US20130236568A1 (en) 2011-01-12 2013-09-12 Ohio University Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof
EP2729526B1 (en) 2011-07-08 2017-10-04 Dow Global Technologies LLC Polyethylene blend composition suitable for blown film, method of producing the same, and films made therefrom
JP6027619B2 (ja) 2011-10-05 2016-11-16 ラシンドラ・エヌ・ボーズ ホスファプラチン系抗腫瘍剤の大規模調製のための効率的プロセス
WO2013052839A1 (en) 2011-10-05 2013-04-11 Bose Rathindra N Efficient processes for large scale preparation of phosphaplatins antitumor agents
MX365635B (es) 2011-10-20 2019-06-10 Nerium Biotechnology Inc Combinacion terapeutica para el tratamiento de cancer.
LT2855496T (lt) * 2012-05-24 2017-04-10 Phosplatin Therapeutics Llc Fosfaplatinos junginių sintezės ir gryninimo būdai ir jų panaudojimas
EP2958568B1 (en) * 2013-02-22 2020-03-04 University Of Houston Phosphaplatins as neuroprotective agents
WO2015127037A1 (en) * 2014-02-19 2015-08-27 University Of Houston System Compositions and methods for the treatment of neurodegenerative diseases
MX370673B (es) 2014-06-11 2019-12-19 Univ Texas Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
EP3397642A1 (en) 2015-12-30 2018-11-07 Atilim Universitesi Dna targeted mono and heterodinuclear complexes
TWI791008B (zh) 2017-01-06 2023-02-01 美商弗斯普萊汀治療股份有限公司 作為供骨癌或血癌治療用之治療劑的磷酸鉑(phosphaplatin)化合物
JP7381083B2 (ja) 2017-09-08 2023-11-15 フォスプラティン テラピューティクス インコーポレイテッド 免疫調節剤としてのホスファプラチン化合物およびその治療的使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291027A (en) 1979-03-07 1981-09-22 Engelhard Minerals & Chemicals Corp. Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes
US4234500A (en) * 1979-03-07 1980-11-18 Engelhard Minerals & Chemicals Corporation Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes
CA2017739A1 (en) * 1989-07-18 1991-01-18 Engelhard Corporation Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents
EP1644388A2 (en) * 2003-06-27 2006-04-12 ODANI, Akira Bisphosphonate complexes
EP2177525A1 (en) * 2007-07-06 2010-04-21 TMRC Co., Ltd. Metal complex compound, cancer therapeutic composition comprising the metal complex compound as active ingredient, and intermediate for production of the metal complex compound
ES2495743T3 (es) * 2007-08-06 2014-09-17 Ohio University Fosfaplatinos y su uso en el tratamiento de cánceres resistentes a cisplatino y carboplatino

Also Published As

Publication number Publication date
SI2173337T1 (sl) 2014-10-30
US8034964B2 (en) 2011-10-11
CY1115504T1 (el) 2017-01-04
US20110313182A1 (en) 2011-12-22
WO2009021082A3 (en) 2009-04-23
US20090042838A1 (en) 2009-02-12
WO2009021081A3 (en) 2009-05-07
PL2173337T3 (pl) 2014-11-28
ES2495743T3 (es) 2014-09-17
WO2009021081A2 (en) 2009-02-12
HRP20140808T1 (hr) 2014-10-24
US20130237503A1 (en) 2013-09-12
CN101801369B (zh) 2012-09-19
HK1143551A1 (en) 2011-01-07
WO2009021082A2 (en) 2009-02-12
EP2173337A4 (en) 2010-10-27
EP2173337A2 (en) 2010-04-14
US20100233293A1 (en) 2010-09-16
JP2010535803A (ja) 2010-11-25
US7700649B2 (en) 2010-04-20
EP2668949A1 (en) 2013-12-04
EP2173337B1 (en) 2014-07-30
CN101801369A (zh) 2010-08-11
US8653132B2 (en) 2014-02-18
JP5647300B2 (ja) 2014-12-24
JP2013227218A (ja) 2013-11-07
US8445710B2 (en) 2013-05-21
PT2173337E (pt) 2014-09-03
DK2173337T3 (da) 2014-09-15

Similar Documents

Publication Publication Date Title
JP5385274B2 (ja) ホスファプラチン、ならびにシスプラチンおよびカルボプラチンに対し耐性を有する癌の治療におけるその使用
US10759820B2 (en) Proliferative disease treatment methods with phosphaplatin complexes
EP3564246B1 (en) A gold(iii) complex, a conjugate of the gold(iii) complex, a pharmaceutical composition comprising the gold(iii) complex and uses and a process for preparing the gold(iii) complex
HK1143551B (en) Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin
EP2344512B1 (en) Platinum complex with antitumor activity
Albaroodi Yasser Synthesis of New Platinum-Based Anti-Cancer Drugs
HK1180605B (en) Phosphaplatins and their use for treatment of cancers
HK1180605A (en) Phosphaplatins and their use for treatment of cancers

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130607

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131003

R150 Certificate of patent or registration of utility model

Ref document number: 5385274

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250